54 Recruiting Studies Using Trametinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Trametinib
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
📍 M D Anderson Cancer Center — Houston, Texas
Stage IIIB Cutaneous Melanoma AJCC v7
View Study & Checklist ➔PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Thyroid Cancer
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Anaplastic Thyroid Cancer
View Study & Checklist ➔Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
📍 UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
Clinical Stage IV Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
📍 Stanford School of Medicine — Stanford, California
Thyroid Gland Anaplastic Carcinoma
View Study & Checklist ➔Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
📍 University of California, Los Angeles — Los Angeles, California
Prostate Cancer
View Study & Checklist ➔Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Metastatic Melanoma
View Study & Checklist ➔Pediatric Long-Term Follow-up and Rollover Study
📍 Phoenix Children s Hospital — Phoenix, Arizona
Diffuse Astrocytoma
View Study & Checklist ➔Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Metastatic Malignant Solid Neoplasm
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
EGFR NP_005219.2:p.S492R
View Study & Checklist ➔Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
📍 Yale University — New Haven, Connecticut
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
📍 The Angeles Clinic and Research Institute — Los Angeles, California
Melanoma
View Study & Checklist ➔A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
📍 University of California, San Francisco — San Francisco, California
Advanced or Metastatic Solid Tumors
View Study & Checklist ➔Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
KRAS Gene Mutation
View Study & Checklist ➔24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Ras/MAPK Pathway Vascular Anomalies
View Study & Checklist ➔Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
📍 Novartis Investigative Site — Toronto, Ontario
EGFR-mutant Non-small Cell Lung Cancer
View Study & Checklist ➔Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
📍 Alberta Children's Hospital — Calgary, Alberta
Low-grade Glioma
View Study & Checklist ➔Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
📍 Arizona Oncology Associates Professional Corporation — Tucson, Arizona
Advanced Solid Tumors
View Study & Checklist ➔Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
📍 Massachusetts General Hospital — Boston, Massachusetts
KRAS G12C Mutant Solid Tumors
View Study & Checklist ➔Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
📍 Northwestern University Med School — Chicago, Illinois
Differentiated Thyroid Cancer (DTC)
View Study & Checklist ➔Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Anaplastic Thyroid Cancer
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
📍 Phoenix Children's Hospital — Phoenix, Arizona
Low Grade Glioma (LGG) of Brain With BRAF Aberration
View Study & Checklist ➔Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Recurrent Uveal Melanoma
View Study & Checklist ➔Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage III Cutaneous Melanoma AJCC v7
View Study & Checklist ➔A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
📍 Mayo Clinic - Arizona — Phoenix, Arizona
Advanced or Metastatic NRAS-mutant Melanoma
View Study & Checklist ➔Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Clinical Stage III Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Clinical Stage III Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
Juvenile Myelomonocytic Leukemia
View Study & Checklist ➔A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Solid Tumors, KRAS Mutation; SOS1
View Study & Checklist ➔Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Anaplastic Astrocytoma
View Study & Checklist ➔Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Hormone-Resistant Prostate Cancer
View Study & Checklist ➔A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Metastatic Thyroid Gland Carcinoma
View Study & Checklist ➔Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
📍 University of Alabama at Birmingham — Birmingham, Alabama
BRAF V600 Mutation
View Study & Checklist ➔Pan Tumor Rollover Study
📍 Local Institution - 0220 — Huntsville, Alabama
Cancer
View Study & Checklist ➔Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
📍 Cook Children's Health Care System — Fort Worth, Texas
Langerhans Cell Histiocytosis
View Study & Checklist ➔Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
📍 University of Alabama at Birmingham, Children's of Alabama — Birmingham, Alabama
Recurrent World Health Organization (WHO) Grade II Glioma
View Study & Checklist ➔A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
📍 Phoenix Children's Hospital — Phoenix, Arizona
Leukemia, Juvenile Myelomonocytic
View Study & Checklist ➔Dabrafenib and/or Trametinib Rollover Study
📍 Honor Health Research Institute — Scottsdale, Arizona
Melanoma
View Study & Checklist ➔Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
📍 University of Iowa — Iowa City, Iowa
Metastatic Melanoma
View Study & Checklist ➔Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Refractory Differentiated Thyroid Gland Carcinoma
View Study & Checklist ➔MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
📍 Children's National Hospital — Washington D.C., District of Columbia
Low Grade Glioma
View Study & Checklist ➔A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Osteosarcoma
View Study & Checklist ➔A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
📍 START Mid West — Grand Rapids, Michigan
Advanced Solid Tumors
View Study & Checklist ➔Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
📍 Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
View Study & Checklist ➔Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
📍 City of Hope Medical Center — Duarte, California
BRAF NP_004324.2:p.V600E
View Study & Checklist ➔A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔